Specify a stock or a cryptocurrency in the search bar to get a summary
89bio Inc
ETNB89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California. Address: 142 Sansome Street, San Francisco, CA, United States, 94104
Analytics
WallStreet Target Price
32.44 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ETNB
Dividend Analytics ETNB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ETNB
Stock Valuation ETNB
Financials ETNB
Results | 2019 | Dynamics |